These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 22896656)

  • 41. Knockdown of ICB-1 gene enhanced estrogen responsiveness of ovarian and breast cancer cells.
    Konwisorz A; Springwald A; Haselberger M; Goerse R; Ortmann O; Treeck O
    Endocr Relat Cancer; 2010 Mar; 17(1):147-57. PubMed ID: 19942713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
    Arcaroli JJ; Quackenbush KS; Powell RW; Pitts TM; Spreafico A; Varella-Garcia M; Bemis L; Tan AC; Reinemann JM; Touban BM; Dasari A; Eckhardt SG; Messersmith WA
    Clin Cancer Res; 2012 May; 18(9):2704-14. PubMed ID: 22553375
    [TBL] [Abstract][Full Text] [Related]  

  • 43. G protein-coupled estrogen receptor (GPER) mediates NSCLC progression induced by 17β-estradiol (E2) and selective agonist G1.
    Liu C; Liao Y; Fan S; Tang H; Jiang Z; Zhou B; Xiong J; Zhou S; Zou M; Wang J
    Med Oncol; 2015 Apr; 32(4):104. PubMed ID: 25744245
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
    Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
    Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.
    Okubo S; Kurebayashi J; Otsuki T; Yamamoto Y; Tanaka K; Sonoo H
    Br J Cancer; 2004 Jan; 90(1):236-44. PubMed ID: 14710235
    [TBL] [Abstract][Full Text] [Related]  

  • 46. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
    Schwarz LJ; Fox EM; Balko JM; Garrett JT; Kuba MG; Estrada MV; González-Angulo AM; Mills GB; Red-Brewer M; Mayer IA; Abramson V; Rizzo M; Kelley MC; Meszoely IM; Arteaga CL
    J Clin Invest; 2014 Dec; 124(12):5490-502. PubMed ID: 25401474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.
    Yamaguchi H; Takanashi M; Yoshida N; Ito Y; Kamata R; Fukami K; Yanagihara K; Sakai R
    Cancer Sci; 2014 May; 105(5):528-36. PubMed ID: 24612061
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation.
    Lokich E; Singh RK; Han A; Romano N; Yano N; Kim K; Moore RG
    Sci Rep; 2014 Jun; 4():5500. PubMed ID: 24975515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells.
    Fan P; Agboke FA; McDaniel RE; Sweeney EE; Zou X; Creswell K; Jordan VC
    Eur J Cancer; 2014 Jan; 50(2):457-68. PubMed ID: 24183378
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
    Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
    Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
    Jacquemetton J; Kassem L; Poulard C; Dahmani A; De Plater L; Montaudon E; Sourd L; Morisset L; El Botty R; Chateau-Joubert S; Vacher S; Bièche I; Treilleux I; Trédan O; Marangoni E; Le Romancer M
    Breast Cancer Res; 2021 May; 23(1):57. PubMed ID: 34020697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
    Long X; Fan M; Bigsby RM; Nephew KP
    Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.
    McDermott MS; Chumanevich AA; Lim CU; Liang J; Chen M; Altilia S; Oliver D; Rae JM; Shtutman M; Kiaris H; Győrffy B; Roninson IB; Broude EV
    Oncotarget; 2017 Feb; 8(8):12558-12575. PubMed ID: 28147342
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression.
    Huang Y; Jiang D; Sui M; Wang X; Fan W
    Oncol Rep; 2017 Feb; 37(2):705-712. PubMed ID: 28000875
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
    Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
    Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human phosphatidylethanolamine-binding protein 4 promotes transactivation of estrogen receptor alpha (ERalpha) in human cancer cells by inhibiting proteasome-dependent ERalpha degradation via association with Src.
    Liu H; Qiu J; Li N; Chen T; Cao X
    J Biol Chem; 2010 Jul; 285(29):21934-42. PubMed ID: 20460377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs).
    Li X; Tao Z; Wang H; Deng Z; Zhou Y; Du Z
    Exp Cell Res; 2020 Nov; 396(1):112261. PubMed ID: 32896567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
    Wang B; Li D; Rodriguez-Juarez R; Farfus A; Storozynsky Q; Malach M; Carpenter E; Filkowski J; Lykkesfeldt AE; Kovalchuk O
    BMC Cancer; 2018 Aug; 18(1):817. PubMed ID: 30103729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
    Gardaneh M; Shojaei S; Kaviani A; Behnam B
    Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.
    Lang L; Shay C; Xiong Y; Thakkar P; Chemmalakuzhy R; Wang X; Teng Y
    J Hematol Oncol; 2018 Jun; 11(1):85. PubMed ID: 29925404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.